SLN Silence Therapeutics Plc - Amer
$19.74▼ -0.23%
Healthcare
Other
Volume 2.30M
Avg Volume (10D) 10.50M
Key Metrics & Fundamentals
Market Cap
$1.23B
P/E Ratio
–
Div Yield
0.00%
52W Range
4.19 - 19.87
% vs 50 MA
50.85%
% vs 200 MA
123.56%
RSI-14
79.8
MACD Histogram
+1.0800
Beta (1Y vs SPY)
1.68
Free Cash Flow
$1.52M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$13.91M
COGS
$0
Operating Exp
$13.87M
Operating Income
-$13.87M
EBIT
-$13.87M
Pretax Income
-$12.27M
Net Income
-$12.27M
EPS (Diluted)
-0.27
Price & Volume History
Loading chart…
Recent News
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
CNW Group · Oct 20, 2026 8:59 AM ET
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
Zacks · Oct 20, 2026 8:55 AM ET
Is Silence Therapeutics (NasdaqGM:SLN) Reasonable Near Its $20 Deal Price?
Simply Wall St. · Oct 19, 2026 9:09 PM ET
Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%
Insider Monkey · Oct 19, 2026 7:41 PM ET
Silence Therapeutics Lands a 130% Takeover Premium
GuruFocus.com · Oct 19, 2026 3:49 PM ET
Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%
Barrons.com · Oct 19, 2026 12:08 PM ET
Silence Therapeutics jumps 59% on Merck takeover
Proactive · Oct 19, 2026 11:20 AM ET
Silence Therapeutics stock soars 125% on Merck acquisition
Investing.com · Oct 19, 2026 9:56 AM ET
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Business Wire · Oct 19, 2026 8:00 AM ET
Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks · Oct 14, 2026 8:35 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See SLN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.